Cargando…

Review of the Clinical Pharmacokinetics and Pharmacodynamics of Alemtuzumab and Its Use in Kidney Transplantation

Alemtuzumab is a humanized monoclonal antibody against CD52 and causes depletion of T and B lymphocytes, monocytes, and NK cells. Alemtuzumab is registered for the treatment of multiple sclerosis (MS) and is also used in chronic lymphocytic leukemia (CLL). Alemtuzumab is used off-label in kidney tra...

Descripción completa

Detalles Bibliográficos
Autores principales:	van der Zwan, Marieke, Baan, Carla C., van Gelder, Teun, Hesselink, Dennis A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2017
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5784003/ https://www.ncbi.nlm.nih.gov/pubmed/28669130 http://dx.doi.org/10.1007/s40262-017-0573-x

Ejemplares similares

Clinical and Molecular Profiling to Develop a Potential Prediction Model for the Response to Alemtuzumab Therapy for Acute Kidney Transplant Rejection
por: Hullegie‐Peelen, Daphne M., et al.
Publicado: (2022)

Costimulation Blockade in Kidney Transplant Recipients
por: van der Zwan, Marieke, et al.
Publicado: (2019)

Comparison of Alemtuzumab and Anti-thymocyte Globulin Treatment for Acute Kidney Allograft Rejection
por: van der Zwan, Marieke, et al.
Publicado: (2020)

Guillain-Barré syndrome and chronic inflammatory demyelinating polyradiculoneuropathy after alemtuzumab therapy in kidney transplant recipients
por: van der Zwan, Marieke, et al.
Publicado: (2020)

A Decade of Experience With Alemtuzumab Therapy for Severe or Glucocorticoid-Resistant Kidney Transplant Rejection
por: van Vugt, Lukas K., et al.
Publicado: (2023)

High Tacrolimus Intrapatient Variability and Subtherapeutic Immunosuppression are Associated With Adverse Kidney Transplant Outcomes
por: Mendoza Rojas, Aleixandra, et al.
Publicado: (2022)

Improved Glucose Tolerance in a Kidney Transplant Recipient With Type 2 Diabetes Mellitus After Switching From Tacrolimus To Belatacept: A Case Report and Review of Potential Mechanisms
por: de Graav, Gretchen N., et al.
Publicado: (2018)

Analysis of NFATc1 amplification in T cells for pharmacodynamic monitoring of tacrolimus in kidney transplant recipients
por: Kannegieter, Nynke M., et al.
Publicado: (2018)

Alemtuzumab as Antirejection Therapy: T Cell Repopulation and Cytokine Responsiveness
por: Bouvy, Anne P., et al.
Publicado: (2016)

Alloreactive T cells to Assess Acute Rejection Risk in Kidney Transplant Recipients
por: Mendoza Rojas, Aleixandra, et al.
Publicado: (2023)

Immunosuppression Has Long-Lasting Effects on Circulating Follicular Regulatory T Cells in Kidney Transplant Recipients
por: Niu, Qian, et al.
Publicado: (2020)

The Efficacy of Rabbit Anti-Thymocyte Globulin for Acute Kidney Transplant Rejection in Patients Using Calcineurin Inhibitor and Mycophenolate Mofetil-Based Immunosuppressive Therapy
por: van der Zwan, Marieke, et al.
Publicado: (2018)

Alemtuzumab induction in pediatric kidney transplantation
por: Kaabak, Michael M, et al.
Publicado: (2013)

Lymphocyte pharmacodynamics are not associated with autoimmunity or efficacy after alemtuzumab
por: Wiendl, Heinz, et al.
Publicado: (2019)

Monitoring the tacrolimus concentration in peripheral blood mononuclear cells of kidney transplant recipients
por: Francke, Marith I., et al.
Publicado: (2020)

Pharmacokinetics, Pharmacodynamics and Pharmacogenetics of Tacrolimus in Kidney Transplantation
por: Yu, Meng, et al.
Publicado: (2018)

Pre-transplant donor-reactive IL-21 producing T cells as a tool to identify an increased risk for acute rejection
por: Mendoza Rojas, Aleixandra, et al.
Publicado: (2021)

Pharmacokinetics and clinical activity of very low-dose alemtuzumab in transplantation for acute leukemia
por: Spyridonidis, A, et al.
Publicado: (2011)

Influence of Probenecid on the Pharmacokinetics and Pharmacodynamics of Sorafenib
por: Hussaarts, Koen G. A. M., et al.
Publicado: (2020)

A Population Pharmacokinetic Model of Whole-Blood and Intracellular Tacrolimus in Kidney Transplant Recipients
por: Franken, Linda G., et al.
Publicado: (2022)

Pharmacokinetic and Pharmacodynamic Considerations in Relation to Calcineurin Usage in Elderly Kidney Transplant Recipients
por: Cossart, Amelia R., et al.
Publicado: (2021)

Immune Subsets From Ficoll Density Gradient Separation in Kidney Transplant Recipients
por: Udomkarnjananun, Suwasin, et al.
Publicado: (2022)

Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Belatacept in Adult Kidney Transplant Recipients
por: Shen, Jinshan, et al.
Publicado: (2013)

Population Pharmacokinetics of Alemtuzumab (Campath) in Pediatric Hematopoietic Cell Transplantation: Towards Individualized Dosing to Improve Outcome
por: Admiraal, Rick, et al.
Publicado: (2019)

Clinical Pharmacokinetic and Pharmacodynamic Profile of Riociguat
por: Frey, Reiner, et al.
Publicado: (2017)

Influence of the Circadian Timing System on Tacrolimus Pharmacokinetics and Pharmacodynamics After Kidney Transplantation
por: Fontova, Pere, et al.
Publicado: (2021)

Response: Commentary: Belatacept Does Not Inhibit Follicular T Cell-Dependent B-Cell Differentiation in Kidney Transplantation
por: Baan, Carla C., et al.
Publicado: (2018)

Direct detection of circulating donor-derived extracellular vesicles in kidney transplant recipients
por: Woud, Wouter W., et al.
Publicado: (2022)

Alemtuzumab Induction and Delayed Acute Rejection in Steroid-Free Simultaneous Pancreas-Kidney Transplant Recipients
por: Bank, Jonna R., et al.
Publicado: (2016)

Urinary Extracellular Vesicles Are a Novel Tool to Monitor Allograft Function in Kidney Transplantation: A Systematic Review
por: Wu, Liang, et al.
Publicado: (2021)

Pharmacokinetic role of protein binding of mycophenolic acid and its glucuronide metabolite in renal transplant recipients
por: de Winter, Brenda C. M., et al.
Publicado: (2009)

Phospho-specific flow cytometry for pharmacodynamic monitoring of immunosuppressive therapy in transplantation
por: Baan, Carla, et al.
Publicado: (2012)

A Population Pharmacokinetic Model to Predict the Individual Starting Dose of Tacrolimus Following Pediatric Renal Transplantation
por: Andrews, Louise M., et al.
Publicado: (2017)

Mast Cells in Kidney Transplant Biopsies With Borderline T Cell-mediated Rejection and Their Relation to Chronicity
por: Varol, Hilal, et al.
Publicado: (2023)

Overweight Kidney Transplant Recipients Are at Risk of Being Overdosed Following Standard Bodyweight-Based Tacrolimus Starting Dose
por: Andrews, Louise M., et al.
Publicado: (2017)

Clinical Pharmacokinetics and Pharmacodynamics of Lenalidomide
por: Chen, Nianhang, et al.
Publicado: (2016)

Clinical Pharmacokinetics and Pharmacodynamics of Micafungin
por: Wasmann, Roeland E., et al.
Publicado: (2017)

Clinical Pharmacokinetics and Pharmacodynamics of Propofol
por: Sahinovic, Marko M., et al.
Publicado: (2018)

Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib
por: Wind, Sven, et al.
Publicado: (2019)

Clinical Pharmacokinetics and Pharmacodynamics of Dalcetrapib
por: Black, Donald M., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_tjj94v3nufde5mah31du7ti8h8